Ambalal Sarabhai Enterprises Ltd
NSE: AMBALALSA BSE: 500009
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
₹31.6
52W: ₹23.1 — ₹40.4
PE 30.3 · Book ₹7.17 · +341% vs bookMarket Cap₹242 Cr
Stock P/E30.3Price to Earnings
ROCE6.01%Return on Capital
ROE6.8%Return on Equity
Div. Yield0%Face Value ₹10
Weaknesses
- −Stock is trading at 4.36 times its book value
- −Promoter holding is low: 31.4%
- −Tax rate seems low
- −Company has a low return on equity of 8.72% over last 3 years.
- −Earnings include an other income of Rs.9.21 Cr.
- −Working capital days have increased from -538 days to 109 days
Shareholding Pattern
Promoters31.36%
FIIs0%
DIIs0%
Public68.64%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 30.78% | 31.35%▲0.6 | 31.35% | 31.35% | 31.35% | 31.35% | 31.36%▲0.0 | 31.36% |
| FIIs | 0% | 0% | 0% | 0.38%▲0.4 | 0.38% | 0.34%▼0.0 | 0.34% | 0%▼0.3 |
| DIIs | 0% | 0% | 0.1%▲0.1 | 0.1% | 0%▼0.1 | 0% | 0% | 0% |
| Public | 69.22% | 68.65%▼0.6 | 68.54%▼0.1 | 68.18%▼0.4 | 68.26%▲0.1 | 68.32%▲0.1 | 68.29%▼0.0 | 68.64%▲0.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.8 | 0.33 | 0.99 | 1.14 | 0 | 1.17 | 1.73 | 1.64 | 0.79 | 0 |
| Expenses | 2.13 | 1.96 | 1.64 | 2.41 | 1.8 | 3.74 | 3.43 | 2.83 | 2.43 | 0.94 |
| Operating Profit | -1.33 | -1.63 | -0.65 | -1.27 | -1.8 | -2.57 | -1.7 | -1.19 | -1.64 | -0.94 |
| OPM % | -166.25% | -493.94% | -65.66% | -111.4% | 0% | -219.66% | -98.27% | -72.56% | -207.59% | 0% |
| Net Profit | 0.56 | -0.65 | 4.7 | 0.46 | 4.31 | 8.43 | -4.96 | 6.88 | -0.38 | 1.84 |
| EPS ₹ | 0.07 | -0.08 | 0.61 | 0.06 | 0.56 | 1.1 | -0.65 | 0.9 | -0.05 | 0.24 |
AI Insights
Revenue Trend
TTM revenue at ₹4.16Cr, up 3% YoY. OPM at -131.49%.
Debt Position
Borrowings at ₹8.76Cr. Debt-to-equity ratio: N/Ax. High leverage — monitor closely.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0% (+0.00pp change). Promoters hold 31.36%.
Margin & Efficiency
ROCE improving from -22.31% (Mar 2014) to 6.01% (Mar 2025). Working capital days: 109.32.
Valuation
PE 30.3x with 6.01% ROCE. Price is 341% above book value of ₹7.17. Dividend yield: 0%.
Recent Announcements
- Board Meeting Intimation for Approval Of Audited Financial Results As On 31.03.2026 14 May - Board meeting on May 21, 2026 to approve audited FY26 results, fix AGM and book closure.
- Intimation Regarding Change In Branch Address Of Registrar & Share Transfer Agent (MCS Share Transfer Agent Limited) 24 Apr - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai.
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 21 Apr - Annual disclosure for FY 2025-26 filed; no incremental borrowing or penalty applicable.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 21 Apr - Company says it is not a Large Corporate for FY ended March 31, 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - We hereby submit Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018. Kindly take the same on your records.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse